A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.
Also called NCT02413398
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 321 participants
- Sponsor
- Registry
-
NCT02413398
-
- Other papers using this trial's data
- Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Canada, Czechia, Italy, Poland, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT02413398. Randomized; double masking; primary purpose treatment. Start 2015-06-15 (actual); primary completion 2017-11-07 (actual). Results posted on 2018-10-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
- Acronym
- DERIVE
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin 10 mg
- Intervention (Drug)
- Matching Placebo for Dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02413398- Content hash
0aa0e0b5eaac9f166230d40b99c1b76d9189d502ca7f6033adf65e510e68386d